Get the Stockscreener App
48.48
0.99%
-0.625
Boston Scientific Corp stock is traded at $48.48, with a volume of 8.12M.
It is down -0.99% in the last 24 hours and down -14.92% over the past month.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
See More
Previous Close:
$49.11
Open:
$48.7238
24h Volume:
8.12M
Relative Volume:
0.47
Market Cap:
$72.12B
Revenue:
$20.62B
Net Income/Loss:
$3.56B
P/E Ratio:
20.33
EPS:
2.3847
Net Cash Flow:
$3.48B
1W Performance:
-15.84%
1M Performance:
-14.92%
6M Performance:
-52.13%
1Y Performance:
-53.47%
1-Day Range:
$48.34
$49.30
1-Week Range:
$48.34
$58.13
52-Week Range:
$48.34
$109.50
Boston Scientific Corp Stock (BSX) Company Profile
Name
Boston Scientific Corp
Sector
Industry
Phone
508-683-4000
Address
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX vs ABT, SYK, MDT, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
48.52 | 72.99B | 20.62B | 3.56B | 3.48B | 2.3847 |
ABT
Abbott Laboratories
|
85.95 | 150.32B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
308.02 | 117.93B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
74.86 | 97.02B | 35.48B | 4.64B | 5.41B | 3.582 |
EW
Edwards Lifesciences Corp
|
87.43 | 49.50B | 6.30B | 1.07B | 1.09B | 1.8406 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-26 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-03-25 | Downgrade | Erste Group | Buy → Hold |
| Sep-08-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-16-25 | Initiated | Leerink Partners | Outperform |
| Apr-16-25 | Upgrade | Needham | Hold → Buy |
| Jan-10-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Oct-18-24 | Downgrade | Needham | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-01-24 | Upgrade | Mizuho | Neutral → Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Jun-30-23 | Initiated | CL King | Buy |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Buy |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-20-22 | Resumed | Citigroup | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-06-22 | Initiated | Wolfe Research | Outperform |
| May-27-22 | Upgrade | Needham | Hold → Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| May-26-21 | Downgrade | Needham | Buy → Hold |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Sep-17-20 | Initiated | Truist | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| Apr-22-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-01-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Buy |
| Dec-30-19 | Reiterated | Cowen | Outperform |
| Dec-19-19 | Downgrade | Needham | Strong Buy → Buy |
| Sep-05-19 | Resumed | JP Morgan | Overweight |
| Sep-03-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-28-18 | Initiated | UBS | Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Oct-02-18 | Reiterated | Morgan Stanley | Overweight |
| Sep-07-18 | Reiterated | Needham | Strong Buy |
| Sep-04-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-06-18 | Reiterated | Needham | Strong Buy |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Apr-26-18 | Reiterated | Needham | Strong Buy |
View All
Boston Scientific Corp Stock (BSX) Latest News
BSX Downgraded by Wolfe Research -- Rating Changed to Peer Perfo - GuruFocus
Wolfe Research cuts Boston Scientific rating as key growth drivers falter - Investing.com Nigeria
Wolfe Research downgrades Boston Scientific stock rating on growth concerns - Investing.com
Boston Scientific’s $1.5B bet signals heart valve market battle - Modern Healthcare News
Barclays Remains a Buy on Boston Scientific (BSX) - The Globe and Mail
Why Boston Scientific Stock Was Sliding This Week - The Motley Fool
Our Boston Scientific Pick Has Suffered. We’re Pulling the Recommendation. - Barron's
Assessing Boston Scientific (BSX) Valuation After Strong SEISMIQ 4CE Trial Results - simplywall.st
Boston Scientific (BSX) Stock Dips While Market Gains: Key Facts - Yahoo Finance
BSX Maintained by Leerink Partners -- Price Target Lowered to $7 - GuruFocus
Press Release: Pablo José Hernández Rivera Visits Boston Scientific in Dorado to Highlight Potential of Medical Manufacturing in Puerto Rico - Quiver Quantitative
This Boston Scientific Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Thursday - Benzinga
Wells Fargo cuts Boston Scientific to ’Equal Weight’ on Watchman slowdown - Investing.com
RBC Capital reiterates Boston Scientific stock rating on Watchman outlook - Investing.com
Citigroup Adjusts Boston Scientific Price Target to $70 From $87, Maintains Buy Rating - marketscreener.com
Bernstein Adjusts Boston Scientific Price Target to $76 From $97, Maintains Outperform Rating - marketscreener.com
Leerink cuts Boston Scientific stock price target on Watchman outlook - Investing.com
Leerink Partners Adjusts PT on Boston Scientific to $74 From $87, Maintains Outperform Rating - marketscreener.com
Wells Fargo Downgrades Boston Scientific to Equalweight From Overweight, Adjusts PT to $55 From $75 - marketscreener.com
Goldman Sachs Adjusts Price Target on Boston Scientific to $71 From $81, Maintains Buy Rating - Moomoo
Barclays Adjusts Price Target on Boston Scientific to $89 From $96, Maintains Overweight Rating - marketscreener.com
Time To Buy The Dip In Boston Scientific Stock? - Trefis
Boston Scientific Stock Falls 12% In A Single Day, Time To Buy The Stock? - Trefis
Stock Market Today, May 27: Boston Scientific Plunges After Reiterating Underwhelming Full Year Growth Guidance - The Motley Fool
Boston Scientific Corp (BSX) Stock Down 12.5% -- Now Undervalued? GF Score: 83/100 - GuruFocus
Boston Scientific (BSX) Device Succeeds in Over 93% of Patients in Its Pivotal Trial - Insider Monkey
Watchman Woes: Boston Scientific Shares Plunge on Weak Demand - Medical Device and Diagnostic industry
Boston Scientific Is the Worst Performing S&P 500 Stock. Here’s Why. - Barron's
Boston Scientific Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Boston Scientific Is Betting $1.5 Billion on a Massive Market -- and Wall Street Is Paying Attention - The Motley Fool
Boston Scientific Is Betting $1.5 Billion on a Massive Market -- and Wall Street Is Paying Attention - The Motley Fool
Boston Scientific (BSX) Plunges 10.3% to $51.69 - AlphaStreet
Boston Scientific hits two-year low after flagging weaker demand for heart device - Reuters
Boston Scientific shares fall 10% on Watchman weakness, competitive pressures - Investing.com
Boston Scientific slides after flagging slowdown in Watchman heart device usage - marketscreener.com
Boston Scientific slides after flagging slowdown in Watchmen heart device usage - AOL.com
Boston Scientific (BSX) Shares Drop 10% Amid Demand Slowdown for WATCHMAN Implant - GuruFocus
Stifel Adjusts Price Target on Boston Scientific to $75 From $85, Maintains Buy Rating - marketscreener.com
Boston Scientific (BSX) slides after management cuts 2026 growth outlook - Quiver Quantitative
Boston Scientific (BSX) Plunges 10% Following Bernstein Conference Guidance Revision - Blockonomi
Here’s Why Boston Scientific Stock (BSX) Is Crashing Today - TipRanks
Boston Scientific falls on Watchman headwinds (BSX:NYSE) - Seeking Alpha
Why is Boston Scientific stock plunging today? - Investing.com
Why is Boston Scientific stock plunging today? By Investing.com - Investing.com Canada
Boston Scientific Down Over 10%, On Track for Lowest Close Since November 2023 -- Data Talk - Moomoo
Cramer’s Stop Trading: Boston Scientific - CNBC
Boston Scientific stock hits 52-week low at $52.29 By Investing.com - Investing.com Nigeria
Boston Scientific stock hits 52-week low at $52.29 - Investing.com
Boston Scientific stock tumbles 6% after guidance cut By Investing.com - Investing.com Australia
Goldman Sachs Adjusts Price Target on Boston Scientific to $81 From $84, Maintains Buy Rating - Moomoo
Boston Scientific makes corporate venture move with MiRus stake - Global Venturing
Boston Scientific Corp Stock (BSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
0.54%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):